A new AI tool, BIOPREVENT, predicts serious post-transplant complications months before symptoms appear using blood biomarkers and clinical data.
Key Details
- 1BIOPREVENT was developed by MUSC Hollings Cancer Center and validated with data from 1,310 transplant recipients.
- 2The tool outperformed standard clinical models in predicting chronic graft-versus-host disease (GVHD) and transplant-related death.
- 3BIOPREVENT uses seven immune protein biomarkers and nine clinical factors to assess risk.
- 4Predictions were validated in an independent patient cohort, showing reliable risk stratification up to 18 months post-transplant.
- 5A free, web-based application is available for clinicians to use the tool for research and risk assessment.
Why It Matters
Early identification of high-risk transplant patients can enable closer monitoring and potential intervention before severe complications arise, representing a significant advance in personalized medicine using AI and biomarker data. This AI tool sets a precedent for broader use of machine learning models to improve outcomes in complex medical scenarios requiring longitudinal risk prediction.
Source
EurekAlert
Related News
•EurekAlert
NYU AI Model Improves 5-Year Breast Cancer Risk Prediction via 3D Mammograms
NYU researchers developed an AI model using longitudinal 3D mammograms that outperforms single-scan and 2D-based tools in predicting 5-year breast cancer risk.
•EurekAlert
Explainable AI Predicts High-Risk Heart Attack Patients for Imaging and Treatment
Researchers developed an explainable AI scoring system to predict intramyocardial hemorrhage risk after severe heart attacks, potentially guiding imaging decisions.
•EurekAlert
AI Framework Accelerates Aortic Aneurysm Risk Prediction from Imaging
Researchers developed BioPINN-LM, combining physics-informed neural networks and multimodal large language models to deliver fast, interpretable risk assessments for ascending thoracic aortic aneurysms.